Atherosclerosis Market

DelveInsight’s Atherosclerosis Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

NEVADA, LA, UNITED STATES, June 20, 2024 /EINPresswire.com/ --
DelveInsight’s “Atherosclerosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Atherosclerosis, historical and forecasted epidemiology as well as the Atherosclerosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Atherosclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Atherosclerosis Market Forecast

Some of the key facts of the Atherosclerosis Market Report:
The Atherosclerosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In June 2023, The US FDA authorized LODOCO (0.5 mg colchicine tablets) as the initial anti-inflammatory cardiovascular treatment proven to lower the risk of cardiovascular death in adult patients with confirmed atherosclerotic disease.
The analysis indicated that approximately 610,000 deaths occur annually in the US due to heart disease. Furthermore, it was noted that about 75% of acute myocardial infarctions in the US are caused by plaque rupture.
During the analysis, it was noted that in high-income countries, the typical age-specific prevalence of peripheral artery disease (PAD) varies from around 5% among individuals aged 40 to 49 years to 13% among those aged 70 to 79 years.
Key Atherosclerosis Companies: Silence Therapeutics, Novartis, Esperion Therapeutics, Agepha Pharma, CSL Behring, Novartis, Merck Sharp & Dohme LLC, Amgen, Ionis Pharmaceuticals, Inc., NewAmsterdam Pharma, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., Silence Therapeutics plc, and others
Key Atherosclerosis Therapies: Zerlasiran, LEQVIO (inclisiran), NEXLETOL (bempedoic acid), LODOCO (colchicine, 0.5 mg tablets), CSL300, Inclisiran, Ertugliflozin, Olpasiran, Olezarsen, Obicetrapib, Tetrahydrobiopterin, MEDI6570, GFH312, SLN360, and others
The Atherosclerosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Atherosclerosis pipeline products will significantly revolutionize the Atherosclerosis market dynamics.

Atherosclerosis Overview
Atherosclerosis is a medical condition characterized by the buildup of plaque (consisting of fats, cholesterol, calcium, and other substances) inside arteries. This buildup thickens and stiffens the artery walls, narrowing the space through which blood can flow. Atherosclerosis is a progressive disease that can lead to various cardiovascular complications, including heart attacks, strokes, and peripheral artery disease.

Get a Free sample for the Atherosclerosis Market Report:
https://www.delveinsight.com/report-store/atherosclerosis-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Atherosclerosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Atherosclerosis Epidemiology Segmentation:
The Atherosclerosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Atherosclerosis
Prevalent Cases of Atherosclerosis by severity
Gender-specific Prevalence of Atherosclerosis
Diagnosed Cases of Episodic and Chronic Atherosclerosis

Download the report to understand which factors are driving Atherosclerosis epidemiology trends @ Atherosclerosis Epidemiology Forecast

Atherosclerosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atherosclerosis market or expected to get launched during the study period. The analysis covers Atherosclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Atherosclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Atherosclerosis Therapies and Key Companies
Zerlasiran: Silence Therapeutics
LEQVIO (inclisiran): Novartis
NEXLETOL (bempedoic acid): Esperion Therapeutics
LODOCO (colchicine, 0.5 mg tablets): Agepha Pharma
CSL300: CSL Behring
Inclisiran: Novartis Pharmaceuticals
Ertugliflozin: Merck Sharp & Dohme LLC
Olpasiran: Amgen
Olezarsen: Ionis Pharmaceuticals, Inc.
Obicetrapib: NewAmsterdam Pharma
Tetrahydrobiopterin: BioMarin Pharmaceutical
MEDI6570: AstraZeneca
GFH312: Zhejiang Genfleet Therapeutics Co., Ltd.
SLN360: Silence Therapeutics plc

Scope of the Atherosclerosis Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Atherosclerosis Companies: Silence Therapeutics, Novartis, Esperion Therapeutics, Agepha Pharma, CSL Behring, Novartis, Merck Sharp & Dohme LLC, Amgen, Ionis Pharmaceuticals, Inc., NewAmsterdam Pharma, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., Silence Therapeutics plc, and others
Key Atherosclerosis Therapies: Zerlasiran, LEQVIO (inclisiran), NEXLETOL (bempedoic acid), LODOCO (colchicine, 0.5 mg tablets), CSL300, Inclisiran, Ertugliflozin, Olpasiran, Olezarsen, Obicetrapib, Tetrahydrobiopterin, MEDI6570, GFH312, SLN360, and others
Atherosclerosis Therapeutic Assessment: Atherosclerosis current marketed and Atherosclerosis emerging therapies
Atherosclerosis Market Dynamics: Atherosclerosis market drivers and Atherosclerosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Atherosclerosis Unmet Needs, KOL’s views, Analyst’s views, Atherosclerosis Market Access and Reimbursement

To know more about Atherosclerosis companies working in the treatment market, visit @ Atherosclerosis Clinical Trials and Therapeutic Assessment

Table of Contents
1. Atherosclerosis Market Report Introduction
2. Executive Summary for Atherosclerosis
3. SWOT analysis of Atherosclerosis
4. Atherosclerosis Patient Share (%) Overview at a Glance
5. Atherosclerosis Market Overview at a Glance
6. Atherosclerosis Disease Background and Overview
7. Atherosclerosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Atherosclerosis
9. Atherosclerosis Current Treatment and Medical Practices
10. Atherosclerosis Unmet Needs
11. Atherosclerosis Emerging Therapies
12. Atherosclerosis Market Outlook
13. Country-Wise Atherosclerosis Market Analysis (2020–2034)
14. Atherosclerosis Market Access and Reimbursement of Therapies
15. Atherosclerosis Market Drivers
16. Atherosclerosis Market Barriers
17. Atherosclerosis Appendix
18. Atherosclerosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.